Pfizer (PFE) Competitors $22.10 +0.19 (+0.87%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PFE vs. JNJ, ABBV, MRK, BMY, ZTS, RPRX, CORT, JAZZ, PRGO, and SUPNShould you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry. Pfizer vs. Johnson & Johnson AbbVie Merck & Co., Inc. Bristol-Myers Squibb Zoetis Royalty Pharma Corcept Therapeutics Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk. Is JNJ or PFE a better dividend stock? Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.2%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.8%. Johnson & Johnson pays out 74.6% of its earnings in the form of a dividend. Pfizer pays out 122.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has raised its dividend for 63 consecutive years and Pfizer has raised its dividend for 16 consecutive years. Do analysts prefer JNJ or PFE? Johnson & Johnson presently has a consensus price target of $171.50, suggesting a potential upside of 11.31%. Pfizer has a consensus price target of $31.07, suggesting a potential upside of 40.59%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than Johnson & Johnson.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Johnson & Johnson 0 Sell rating(s) 8 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.61Pfizer 1 Sell rating(s) 8 Hold rating(s) 5 Buy rating(s) 3 Strong Buy rating(s) 2.59 Does the MarketBeat Community prefer JNJ or PFE? Pfizer received 386 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 68.93% of users gave Pfizer an outperform vote while only 64.88% of users gave Johnson & Johnson an outperform vote. CompanyUnderperformOutperformJohnson & JohnsonOutperform Votes112564.88% Underperform Votes60935.12% PfizerOutperform Votes151168.93% Underperform Votes68131.07% Do institutionals and insiders have more ownership in JNJ or PFE? 69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is JNJ or PFE more profitable? Johnson & Johnson has a net margin of 18.20% compared to Pfizer's net margin of 12.62%. Johnson & Johnson's return on equity of 34.24% beat Pfizer's return on equity.Company Net Margins Return on Equity Return on Assets Johnson & Johnson18.20% 34.24% 13.63% Pfizer 12.62%19.47%8.09% Which has more volatility and risk, JNJ or PFE? Johnson & Johnson has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Does the media refer more to JNJ or PFE? In the previous week, Johnson & Johnson and Johnson & Johnson both had 125 articles in the media. Johnson & Johnson's average media sentiment score of 0.96 beat Pfizer's score of 0.57 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 72 Very Positive mention(s) 12 Positive mention(s) 26 Neutral mention(s) 7 Negative mention(s) 3 Very Negative mention(s) Positive Pfizer 53 Very Positive mention(s) 11 Positive mention(s) 28 Neutral mention(s) 27 Negative mention(s) 4 Very Negative mention(s) Positive Which has stronger earnings & valuation, JNJ or PFE? Johnson & Johnson has higher revenue and earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJohnson & Johnson$88.82B4.18$14.07B$6.6523.17Pfizer$63.63B1.97$8.03B$1.4115.67 SummaryJohnson & Johnson beats Pfizer on 15 of the 21 factors compared between the two stocks. Remove Ads Get Pfizer News Delivered to You Automatically Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PFE vs. The Competition Export to ExcelMetricPfizerPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$125.34B$6.35B$5.35B$18.52BDividend Yield7.88%3.23%5.11%4.25%P/E Ratio15.676.7721.6531.06Price / Sales1.97228.59376.3226.47Price / Cash6.3865.6738.1517.54Price / Book1.405.886.444.29Net Income$8.03B$141.32M$3.20B$1.02B7 Day Performance-2.39%5.18%6.67%4.23%1 Month Performance-14.12%-12.93%-6.27%-6.79%1 Year Performance-14.54%-14.85%8.56%-0.03% Pfizer Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PFEPfizer4.9986 of 5 stars$22.10+0.9%$31.07+40.6%-15.4%$125.34B$63.63B15.6783,000JNJJohnson & Johnson4.7468 of 5 stars$150.42-1.8%$171.33+13.9%+2.8%$362.22B$88.82B22.60152,700Upcoming EarningsAnalyst ForecastShort Interest ↓Positive NewsABBVAbbVie4.8851 of 5 stars$185.51-0.8%$211.45+14.0%+7.8%$327.91B$56.33B77.2450,000Positive NewsMRKMerck & Co., Inc.4.9993 of 5 stars$80.99-0.6%$117.12+44.6%-37.1%$204.43B$64.17B12.0369,000BMYBristol-Myers Squibb4.6967 of 5 stars$54.72-1.0%$57.86+5.7%+5.0%$111.22B$48.30B-12.3734,300Analyst ForecastShort Interest ↓Positive NewsZTSZoetis4.5919 of 5 stars$149.90-1.2%$215.90+44.0%-0.4%$67.26B$9.26B27.4614,100Analyst ForecastPositive NewsGap DownRPRXRoyalty Pharma4.5106 of 5 stars$30.93-0.6%$41.60+34.5%+13.2%$17.89B$2.26B21.4080Positive NewsCORTCorcept Therapeutics4.3282 of 5 stars$74.74+0.4%$143.25+91.7%+191.9%$7.89B$675.04M59.32300Insider TradePositive NewsGap UpJAZZJazz Pharmaceuticals4.8861 of 5 stars$106.77-3.0%$187.71+75.8%-9.1%$6.48B$4.07B15.043,200Positive NewsGap DownPRGOPerrigo4.8848 of 5 stars$25.97-1.3%$33.00+27.1%-18.9%$3.55B$4.37B-22.248,900News CoveragePositive NewsSUPNSupernus Pharmaceuticals2.6404 of 5 stars$32.76+0.0%$36.00+9.9%+4.7%$1.83B$661.82M30.62580 Remove Ads Related Companies and Tools Related Companies Johnson & Johnson Alternatives AbbVie Alternatives Merck & Co., Inc. Alternatives Bristol-Myers Squibb Alternatives Zoetis Alternatives Royalty Pharma Alternatives Corcept Therapeutics Alternatives Jazz Pharmaceuticals Alternatives Perrigo Alternatives Supernus Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PFE) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pfizer Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pfizer With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PFE Stock Free PFE Stock Alerts